These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 32486934)

  • 21. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
    Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA
    Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resorption of immune deposits in membranous lupus nephritis following rituximab vs conventional immunosuppressive treatment.
    Zickert A; Lannfelt K; Schmidt Mende J; Sundelin B; Gunnarsson I
    Rheumatology (Oxford); 2021 Jul; 60(7):3443-3450. PubMed ID: 33367774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lupus Nephritis in Asia: Clinical Features and Management.
    Yap DY; Chan TM
    Kidney Dis (Basel); 2015 Sep; 1(2):100-9. PubMed ID: 27536670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term renal survival of paediatric patients with lupus nephritis.
    Demir S; Gülhan B; Özen S; Çeleğen K; Batu ED; Taş N; Orhan D; Bilginer Y; Düzova A; Ozaltin F; Topaloğlu R
    Nephrol Dial Transplant; 2022 May; 37(6):1069-1077. PubMed ID: 33826705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study.
    Zhang X; Huang H; Gao D; Zhao J; Ji L; Fan Y; Hao Y; Zhang Z
    Rheumatol Ther; 2023 Oct; 10(5):1199-1213. PubMed ID: 37418122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.
    Reis-Neto ETD; Seguro LPC; Sato EI; Borba EF; Klumb EM; Costallat LTL; Medeiros MMDC; Bonfá E; Araújo NC; Appenzeller S; Montandon ACOES; Yuki EFN; Teixeira RCA; Telles RW; Egypto DCSD; Ribeiro FM; Gasparin AA; Junior ASA; Neiva CLS; Calderaro DC; Monticielo OA
    Adv Rheumatol; 2024 Jun; 64(1):48. PubMed ID: 38890752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.
    Lee YH; Woo JH; Choi SJ; Ji JD; Song GG
    Lupus; 2010 May; 19(6):703-10. PubMed ID: 20064907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.
    Henderson LK; Masson P; Craig JC; Roberts MA; Flanc RS; Strippoli GF; Webster AC
    Am J Kidney Dis; 2013 Jan; 61(1):74-87. PubMed ID: 23182601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.
    Kamanamool N; McEvoy M; Attia J; Ingsathit A; Ngamjanyaporn P; Thakkinstian A
    Medicine (Baltimore); 2010 Jul; 89(4):227-235. PubMed ID: 20616662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
    Smith E; Al-Abadi E; Armon K; Bailey K; Ciurtin C; Davidson J; Gardner-Medwin J; Haslam K; Hawley D; Leahy A; Leone V; McErlane F; Mewar D; Modgil G; Moots R; Pilkington C; Ramanan A; Rangaraj S; Riley P; Sridhar A; Wilkinson N; Beresford MW; Hedrich CM
    Lupus; 2019 Apr; 28(5):613-620. PubMed ID: 30871425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.
    Condon MB; Ashby D; Pepper RJ; Cook HT; Levy JB; Griffith M; Cairns TD; Lightstone L
    Ann Rheum Dis; 2013 Aug; 72(8):1280-6. PubMed ID: 23740227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis.
    Tian SY; Feldman BM; Beyene J; Brown PE; Uleryk EM; Silverman ED
    J Rheumatol; 2014 Oct; 41(10):1998-2007. PubMed ID: 25225281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab treatment in resistant lupus nephritis: A single-center prospective study.
    Alam S; Mazumder MA; Sharma M; Mahanta PJ; Parry MA; Doley PK
    Clin Nephrol; 2024 Jul; 102():1-7. PubMed ID: 38660888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment for lupus nephritis.
    Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
    Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive Therapies for the Maintenance Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis.
    Tian SY; Feldman BM; Beyene J; Brown PE; Uleryk EM; Silverman ED
    J Rheumatol; 2015 Aug; 42(8):1392-400. PubMed ID: 26077406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
    Atisha-Fregoso Y; Malkiel S; Harris KM; Byron M; Ding L; Kanaparthi S; Barry WT; Gao W; Ryker K; Tosta P; Askanase AD; Boackle SA; Chatham WW; Kamen DL; Karp DR; Kirou KA; Sam Lim S; Marder B; McMahon M; Parikh SV; Pendergraft WF; Podoll AS; Saxena A; Wofsy D; Diamond B; Smilek DE; Aranow C; Dall'Era M
    Arthritis Rheumatol; 2021 Jan; 73(1):121-131. PubMed ID: 32755035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.
    Rosli FZ; Shaharir SS; Abdul Gafor AH; Mohd R; Aizuddin AN; Osman S
    Lupus; 2022 Aug; 31(9):1138-1146. PubMed ID: 35608373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?
    Hogan J; Schwenk MH; Radhakrishnan J
    Kidney Int; 2012 Dec; 82(12):1256-60. PubMed ID: 22648298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of tacrolimus versus mycophenolate mofetil as induction treatment and low-dose tacrolimus as treatment for lupus nephritis: a meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2023 Nov; 82(9):754-762. PubMed ID: 36607421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.
    Mak A; Cheak AA; Tan JY; Su HC; Ho RC; Lau CS
    Rheumatology (Oxford); 2009 Aug; 48(8):944-52. PubMed ID: 19494179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.